查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600163

神经保护市场：按产品、治疗、给药途径、应用和最终用户 - 全球预测 2025-2030

Neuroprotection Market by Product, Treatment, Route of Administration, Application, End Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年神经保护市场价值为2,909.8亿美元，预估2024年将达3,117.9亿美元，复合年增长率为7.63%，至2030年将达4,868.9亿美元。

神经保护是指在面对急性或慢性神经退化性疾病时维持神经元结构和功能的策略和机制。随着世界人口老化，阿兹海默症、帕金森氏症和中风等神经退化性疾病的发生率不断增加，因此需要进行神经保护干预。神经保护应用涵盖药品、生物技术产品和生活方式干预，最终用途为医院、研究机构和学术实验室。市场洞察指出，由于基因组学和药物发现的持续研究、对个人化医疗的兴趣日益浓厚以及政府在医疗保健方面的资金增加，其范围正在扩大。 CRISPR 和基因治疗等技术进步是重要的成长动力。人工智慧在携带式诊断工具和预测分析中的兴起也带来了巨大的机会。主要影响因素包括对非侵入性治疗方案的需求和新型药物传输系统的快速发展。然而，市场面临临床测试高成本、监管障碍以及神经保护药物潜在副作用等挑战。此外，缺乏长期结果的综合资料集。对于公司来说，一条有价值的前进道路是专注于创新策略，例如开发跨越血脑障壁的小分子药物以及利用机器学习演算法对患者进行分层。多标靶药物和联合治疗的研究和开发有可能显着提高治疗效果。生物技术公司和学术机构之间的创新合作可以加速发现并创造竞争。专注于强大的资料分析和遵守新的法规结构可以减少市场进入障碍。神经保护市场呈现广泛的成长潜力，特别是随着市场开拓的扩大，但持续成长和保持相关性需要仔细规避现有限制并专注于科学进步和市场差异化，战略重点至关重要。

主要市场统计
基准年[2023] 2909.8亿美元
预测年份 [2024] 3117.9亿美元
预测年份 [2030] 4868.9亿美元
复合年增长率（%） 7.63%

市场动态：揭示快速发展的神经保护市场的关键市场洞察

供需的动态交互作用正在改变神经保护市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 神经退化性疾病盛行率的上升增加了对神经保护疗法的需求
    • 更重视预防医学和生活方式的改变，以减少危险因素
    • 提高医疗专业人员和患者对神经系统疾病的认识
  • 市场限制因素
    • 血脑障壁的复杂性限制了神经保护剂的传递和功效
  • 市场机会
    • 增加研发投资以开发非侵入性和预防性神经保护策略
    • 开发个人化的神经保护疗法和可客製化的治疗计划
  • 市场问题
    • 严格的监管要求阻碍了神经保护疗法的开发和核准

波特五力：驾驭神经保护市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解神经保护市场的外部影响

外部宏观环境因素在塑造神经保护市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解神经保护市场的竞争格局

对神经保护市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：神经保护市场供应商的绩效评估

FPNV定位矩阵是评估神经保护市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：规划神经保护市场的成功之路

神经保护市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争格局中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3. 塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 神经退化性疾病盛行率的上升增加了对神经保护疗法的需求
      • 更重视预防医学和生活方式的改变，以减少危险因素
      • 提高医疗保健专业人员和患者对神经系统疾病的认识
    • 抑制因素
      • 血脑障壁的复杂性限制了神经保护剂的传递和功效
    • 机会
      • 增加研发投资，制定非侵入性和预防性神经保护策略
      • 开发个人化的神经保护疗法和可客製化的治疗计划
    • 任务
      • 严格的监管要求阻碍了神经保护疗法的开发和核准
  • 市场区隔分析
    • 产品：增加细胞凋亡抑制剂的使用以维持神经元存活并防止神经退化的进展
    • 应用：具有健康意识的消费者越来越偏好神经保护性预防
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章神经保护市场：副产品

  • 介绍
  • 凋亡抑制剂
  • 游离发炎剂
  • 麸胺酸拮抗剂
  • 金属离子螯合剂
  • 神经营养因子
  • 自由基清除剂
  • 兴奋剂

第七章神经保护市场：依治疗分类

  • 介绍
  • 阿兹海默症
  • 肌萎缩侧索硬化症
  • 脑损伤
  • 亨丁顿舞蹈症
  • 多发性硬化症
  • 神经病变
  • 眼睛退化
  • 帕金森氏症

第八章神经保护市场：依给药途径

  • 介绍
  • 椎管内的
  • 静脉
  • 口服
  • 经皮的

第九章神经保护市场：依应用分类

  • 介绍
  • 预防
  • 治疗

第10章神经保护市场：依最终用户分类

  • 介绍
  • 学术研究所
  • 诊所
  • 医院
  • 製药和生物技术公司

第十一章美洲神经保护市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太神经保护市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的神经保护市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 波士顿科学公司收购 Silk Road Medical 以获得尖端 TCAR 技术，加强神经血管产品组合
    • Silk Road Medical 推出 Enroute plus 经颈动脉系统，重点在于神经保护
    • Astracy Pharmaceuticals 开始缺血性中风治疗 AST-004 的 2 期测试并向前推进
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Abcam PLC by Danaher Corporation
  • Anavex Life Sciences corp.
  • AstraZeneca PLC
  • Astrocyte Pharmaceuticals Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol Myers Squibb Company（BMS）
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Neuren Pharmaceuticals
  • Novartis AG
  • Pfizer Inc.
  • Reata Pharmaceuticals, Inc.
  • Sage Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-430D42AA0F33

The Neuroprotection Market was valued at USD 290.98 billion in 2023, expected to reach USD 311.79 billion in 2024, and is projected to grow at a CAGR of 7.63%, to USD 486.89 billion by 2030.

Neuroprotection refers to strategies and mechanisms aimed at preserving the structure and function of neurons in the face of acute or chronic neurodegenerative insults. The necessity of neuroprotective interventions arises from the increasing incidence of neurodegenerative diseases like Alzheimer's, Parkinson's, and stroke due to the aging global population. The application of neuroprotection spans pharmaceuticals, biotechnology products, and lifestyle interventions, with end-use seen in hospitals, research, and academic laboratories. Market insight points to an expanding scope due to ongoing research in genomics and drug discovery, burgeoning interest in personalized medicine, and increased governmental funding in healthcare. Technological advancements, such as CRISPR and gene therapy, are significant growth drivers. The rise of portable diagnostic tools and AI in predictive analytics also presents major opportunities. Key influencing factors include the demand for non-invasive treatment options and the rapid development of novel drug delivery systems. However, the market faces challenges like high costs of clinical trials, regulatory hurdles, and potential side effects of neuroprotective drugs. Additionally, there is a shortage of comprehensive datasets for long-term outcomes. For businesses, a focus on innovative strategies such as developing small-molecule drugs that cross the blood-brain barrier and leveraging machine learning algorithms for patient stratification are valuable pathways. Research and development into multi-target drugs or combination therapies could significantly enhance therapeutic efficacy. Innovative collaborations between biotech firms and academic institutions could accelerate discoveries, providing a competitive edge. Emphasizing robust data analysis and compliance with emerging regulatory frameworks will ease market entry barriers. While the neuroprotection market shows promising growth potential, particularly with expanding therapeutic development, careful navigation around existing limitations and a strategic focus on scientific advancement and market differentiation are essential for sustained growth and relevance.

KEY MARKET STATISTICS
Base Year [2023] USD 290.98 billion
Estimated Year [2024] USD 311.79 billion
Forecast Year [2030] USD 486.89 billion
CAGR (%) 7.63%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neuroprotection Market

The Neuroprotection Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of neurodegenerative diseases increasing the need for neuroprotective therapies
    • Growing focus on preventive healthcare and lifestyle changes to reduce risk factors
    • Increased awareness among healthcare professionals and patients about neurological conditions
  • Market Restraints
    • Complexity of blood-brain barrier limiting delivery and efficacy of neuroprotective agents
  • Market Opportunities
    • Increasing investments in R&D for the development of non-invasive and preventive neuroprotective strategies
    • Development of personalized neuroprotective therapies and customizable treatment plans
  • Market Challenges
    • Stringent regulatory requirements hindering the development and approval of neuroprotective therapies

Porter's Five Forces: A Strategic Tool for Navigating the Neuroprotection Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neuroprotection Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neuroprotection Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neuroprotection Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neuroprotection Market

A detailed market share analysis in the Neuroprotection Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neuroprotection Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neuroprotection Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neuroprotection Market

A strategic analysis of the Neuroprotection Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuroprotection Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Abcam PLC by Danaher Corporation, Anavex Life Sciences corp., AstraZeneca PLC, Astrocyte Pharmaceuticals Inc., Bayer AG, Biogen Inc., Bristol Myers Squibb Company (BMS)., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Ionis Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Neuren Pharmaceuticals, Novartis AG, Pfizer Inc., Reata Pharmaceuticals, Inc., Sage Therapeutics, Inc., Sangamo Therapeutics, Inc., Sanofi S.A., Sunovion Pharmaceuticals Inc, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Neuroprotection Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Apoptosis Inhibitors, Free Anti-Inflammatory Agents, Glutamate Antagonists, Metal Ion Chelators, Neurotrophic Factors, Radical Trapping Agents, and Stimulants.
  • Based on Treatment, market is studied across Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Brain Injury, Huntington's Disease, Multiple Sclerosis, Neuropathies, Ocular Degeneration, and Parkinson's Disease.
  • Based on Route of Administration, market is studied across Intrathecal, Intravenous, Oral, and Transdermal.
  • Based on Application, market is studied across Prevention and Treatment.
  • Based on End Users, market is studied across Academic & Research Institutes, Clinics, Hospitals, and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of neurodegenerative diseases increasing the need for neuroprotective therapies
      • 5.1.1.2. Growing focus on preventive healthcare and lifestyle changes to reduce risk factors
      • 5.1.1.3. Increased awareness among healthcare professionals and patients about neurological conditions
    • 5.1.2. Restraints
      • 5.1.2.1. Complexity of blood-brain barrier limiting delivery and efficacy of neuroprotective agents
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investments in R&D for the development of non-invasive and preventive neuroprotective strategies
      • 5.1.3.2. Development of personalized neuroprotective therapies and customizable treatment plans
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements hindering the development and approval of neuroprotective therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Growing utilization of apoptosis inhibitors to maintain neuronal survival and prevent the progression of neurodegeneration
    • 5.2.2. Application: Growing preference for prevention of neuroprotection among health-conscious consumers
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neuroprotection Market, by Product

  • 6.1. Introduction
  • 6.2. Apoptosis Inhibitors
  • 6.3. Free Anti-Inflammatory Agents
  • 6.4. Glutamate Antagonists
  • 6.5. Metal Ion Chelators
  • 6.6. Neurotrophic Factors
  • 6.7. Radical Trapping Agents
  • 6.8. Stimulants

7. Neuroprotection Market, by Treatment

  • 7.1. Introduction
  • 7.2. Alzheimer's Disease
  • 7.3. Amyotrophic Lateral Sclerosis
  • 7.4. Brain Injury
  • 7.5. Huntington's Disease
  • 7.6. Multiple Sclerosis
  • 7.7. Neuropathies
  • 7.8. Ocular Degeneration
  • 7.9. Parkinson's Disease

8. Neuroprotection Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intrathecal
  • 8.3. Intravenous
  • 8.4. Oral
  • 8.5. Transdermal

9. Neuroprotection Market, by Application

  • 9.1. Introduction
  • 9.2. Prevention
  • 9.3. Treatment

10. Neuroprotection Market, by End Users

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
  • 10.3. Clinics
  • 10.4. Hospitals
  • 10.5. Pharmaceutical & Biotechnology Companies

11. Americas Neuroprotection Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Neuroprotection Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Neuroprotection Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Boston Scientific to enhance neurovascular portfolio with Silk Road Medical acquisition for cutting-edge TCAR technology
    • 14.3.2. Silk Road Medical's introduction of the Enroute plus transcarotid system emphasizing neuroprotection
    • 14.3.3. Astrocyte Pharmaceuticals moves forward with AST-004 as it enters phase 2 trials for ischemic stroke treatment
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Abcam PLC by Danaher Corporation
  • 3. Anavex Life Sciences corp.
  • 4. AstraZeneca PLC
  • 5. Astrocyte Pharmaceuticals Inc.
  • 6. Bayer AG
  • 7. Biogen Inc.
  • 8. Bristol Myers Squibb Company (BMS).
  • 9. Daiichi Sankyo Company, Limited
  • 10. Eisai Co., Ltd.
  • 11. Eli Lilly and Company
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. GlaxoSmithKline PLC
  • 14. Ionis Pharmaceuticals, Inc.
  • 15. Johnson & Johnson Services, Inc.
  • 16. Merck & Co., Inc.
  • 17. Neuren Pharmaceuticals
  • 18. Novartis AG
  • 19. Pfizer Inc.
  • 20. Reata Pharmaceuticals, Inc.
  • 21. Sage Therapeutics, Inc.
  • 22. Sangamo Therapeutics, Inc.
  • 23. Sanofi S.A.
  • 24. Sunovion Pharmaceuticals Inc
  • 25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. NEUROPROTECTION MARKET RESEARCH PROCESS
  • FIGURE 2. NEUROPROTECTION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. NEUROPROTECTION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. NEUROPROTECTION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEUROPROTECTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEUROPROTECTION MARKET DYNAMICS
  • TABLE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY APOPTOSIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY FREE ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY METAL ION CHELATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEUROPROTECTION MARKET SIZE, BY RADICAL TRAPPING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEUROPROTECTION MARKET SIZE, BY STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEUROPROTECTION MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEUROPROTECTION MARKET SIZE, BY BRAIN INJURY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEUROPROTECTION MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROPATHIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NEUROPROTECTION MARKET SIZE, BY OCULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEUROPROTECTION MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NEUROPROTECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEUROPROTECTION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NEUROPROTECTION MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NEUROPROTECTION MARKET SIZE, BY PREVENTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEUROPROTECTION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL NEUROPROTECTION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. SINGAPORE NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. SINGAPORE NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. SINGAPORE NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. SINGAPORE NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. TAIWAN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. TAIWAN NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. TAIWAN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. TAIWAN NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. THAILAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. THAILAND NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. THAILAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. THAILAND NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. VIETNAM NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. VIETNAM NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. VIETNAM NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. VIETNAM NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. DENMARK NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. DENMARK NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. DENMARK NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. DENMARK NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. EGYPT NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. EGYPT NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. EGYPT NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. EGYPT NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. FINLAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. FINLAND NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. FINLAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. FINLAND NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. FRANCE NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. FRANCE NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. FRANCE NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. FRANCE NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. GERMANY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 163. GERMANY NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. GERMANY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. GERMANY NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. ISRAEL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 168. ISRAEL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. ISRAEL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. ISRAEL NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. ITALY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 173. ITALY NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. ITALY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. ITALY NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 178. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. NIGERIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. NIGERIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. NIGERIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. NIGERIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. NORWAY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 188. NORWAY NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. NORWAY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. NORWAY NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. POLAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 193. POLAND NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. POLAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. POLAND NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. QATAR NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 198. QATAR NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. QATAR NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. QATAR NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 202. RUSSIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 203. RUSSIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. RUSSIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. RUSSIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 208. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 217. SPAIN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 218. SPAIN NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. SPAIN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SPAIN NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. SWEDEN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 223. SWEDEN NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. SWEDEN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. SWEDEN NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 228. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 232. TURKEY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 233. TURKEY NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. TURKEY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. TURKEY NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 243. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 246. NEUROPROTECTION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 247. NEUROPROTECTION MARKET, FPNV POSITIONING MATRIX, 2023